Hederagenin (Synonyms: 常春藤皂苷元)

目录号: HY-N0256 纯度: 99.95%: FAQs
Data Sheet SDS COA 产品使用指南技术支持

Hederagenin 是三萜皂苷，具有口服活性和抗肿瘤活性。Hederagenin 能够抑制细胞中由于 LPS 刺激引起的 iNOS，COX-2，和 NF-κB 的表达。Hederagenin 还增加癌细胞中 ROS 产生，破坏线粒体膜电位，诱导细胞凋亡 (apoptosis)。Hederagenin 还增加癌细胞对 Cisplatin (HY-17394) 和 Paclitaxel (HY-B0015) 敏感，增强诱导的细胞凋亡。Hederagenin 对酒精性肝损伤也有预防潜力。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Hederagenin Chemical Structure

CAS No. : 465-99-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
5 mg	￥250	In-stock
10 mg	￥400	In-stock
25 mg	￥790	In-stock
50 mg	￥1300	In-stock
100 mg		询价
200 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Hederagenin:

Hederagenin (Standard) 询价

MCE 顾客使用本产品发表的 3 篇科研文献

Hederagenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看所有亚型

COX COX-1 COX-2 COX-3

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

生物活性
纯度 & 产品资料
参考文献

生物活性

Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury^[1]^[2]^[3]^[4]^[5]^[6].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
518A2	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 27017553]
518A2	EC₅₀	34.9 μM Compound: He	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
8505C	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 27017553]
8505C	EC₅₀	38 μM Compound: He	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
A2780	EC₅₀	> 30 μM Compound: He	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
A2780	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 27017553]
A2780	EC₅₀	> 60 μM Compound: He	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
A2780	EC₅₀	19.9 μM Compound: He	Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
A-375	EC₅₀	> 60 μM Compound: He	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
A549	IC₅₀	> 10 μM Compound: Hederagenin	Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay	[PMID: 31718182]
A549	IC₅₀	> 10 μM Compound: Hederagenin	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
A549	IC₅₀	> 100 μM Compound: alpha-hederagenin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29040953]
A549	IC₅₀	> 200 μM Compound: 3	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 27017553]
A549	IC₅₀	10.249 μM Compound: Hederagenin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
A549	EC₅₀	29 μM Compound: He	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
A549	IC₅₀	38.64 μM Compound: HE	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
A549	IC₅₀	39 μM Compound: 3	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
AGS	IC₅₀	36.14 μM Compound: alpha-hederagenin	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 29040953]
BC	IC₅₀	> 5 μg/mL Compound: Hederagenin	Cytotoxicity against human BC cells by colorimetric method Cytotoxicity against human BC cells by colorimetric method	[PMID: 16038539]
BGC-823	IC₅₀	52.07 μM Compound: alpha-hederagenin	Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay	[PMID: 29040953]
DLD-1	IC₅₀	> 100 μM Compound: 3	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	> 200 μM Compound: 3	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
FaDu	EC₅₀	> 30 μM Compound: He	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
FaDu	EC₅₀	> 60 μM Compound: He	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
HeLa	IC₅₀	42.27 μM Compound: HE	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HeLa	IC₅₀	53.96 μM Compound: alpha-hederagenin	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29040953]
HepG2	CC₅₀	> 1000 μM Compound: He	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29024910]
HepG2	IC₅₀	> 20 μM Compound: 15	Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay	[PMID: 21870831]
HepG2	IC₅₀	28.05 μM Compound: HE	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HL-60	IC₅₀	27.52 μM Compound: HE	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]
HT-29	EC₅₀	> 30 μM Compound: He	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
HT-29	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 27017553]
HT-29	EC₅₀	> 60 μM Compound: He	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
HT-29	EC₅₀	50 μM Compound: He	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
KB	IC₅₀	> 10 μM Compound: Hederagenin	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
KB	IC₅₀	> 10 μM Compound: Hederagenin	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
KB	IC₅₀	> 5 μg/mL Compound: Hederagenin	Cytotoxicity against human KB cells by colorimetric method Cytotoxicity against human KB cells by colorimetric method	[PMID: 16038539]
KB	IC₅₀	14.631 μM Compound: Hederagenin	Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
KB	IC₅₀	54.43 μM Compound: alpha-hederagenin	Antiproliferative activity against human KB cells after 72 hrs by MTT assay Antiproliferative activity against human KB cells after 72 hrs by MTT assay	[PMID: 29040953]
M14	IC₅₀	58 μM Compound: 6	Cytotoxicity against human M14 cells after 48 hrs by MTT assay Cytotoxicity against human M14 cells after 48 hrs by MTT assay	[PMID: 21954959]
MCF7	IC₅₀	> 10 μM Compound: Hederagenin	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MCF7	IC₅₀	> 10 μM Compound: Hederagenin	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
MCF7	EC₅₀	> 30 μM Compound: He	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
MCF7	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 27017553]
MCF7	EC₅₀	25.7 μM Compound: He	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	[PMID: 26476750]
MCF7	IC₅₀	39.389 μM Compound: Hederagenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
MDA-MB-231	IC₅₀	> 10 μM Compound: Hederagenin	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	[PMID: 31718182]
MDA-MB-231	IC₅₀	> 10 μM Compound: Hederagenin	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 29131631]
MDA-MB-231	IC₅₀	36.609 μM Compound: Hederagenin	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28237662]
MKN-45	IC₅₀	53.69 μM Compound: alpha-hederagenin	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 29040953]
NCI-H187	IC₅₀	> 5 μg/mL Compound: Hederagenin	Cytotoxicity against human NCI-H187 cells by colorimetric method Cytotoxicity against human NCI-H187 cells by colorimetric method	[PMID: 16038539]
NCI-H1975	IC₅₀	> 10 μM Compound: Hederagenin	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	> 10 μM Compound: Hederagenin	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NIH3T3	EC₅₀	> 30 μM Compound: He	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
NIH3T3	EC₅₀	> 30 μM Compound: He; Hederagenin	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 27017553]
Sf9	IC₅₀	> 20 μM Compound: Hederagenin	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	> 20 μM Compound: Hederagenin	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
Sf9	IC₅₀	> 20 μM Compound: Hederagenin	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
SW-1736	EC₅₀	> 30 μM Compound: He	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	[PMID: 30840925]
SW-1736	EC₅₀	> 60 μM Compound: He	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	[PMID: 29024910]
U-87MG ATCC	IC₅₀	35.95 μM Compound: HE	Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 23992864]

体外研究
(In Vitro)

Hederagenin (1 μM, 2 μM; 48 h) 破坏线粒体膜电位，增加细胞内活性氧 (ROS) 含量，对癌细胞具有细胞毒作用^[4]。
Hederagenin (1 μM, 2 μM; 48 h) 诱导人结肠癌 LoVo 细胞凋亡，上调凋亡相关蛋白 (Bax)，并降低凋亡抑制蛋白 (Bcl-2、Bcl-xL 和 Survivin) 水平^[4]。
Hederagenin (50 μM; 4 h) 还阻断自噬流诱导的 ROS 积累，增强了 Cisplatin 和 Paclitaxel 在肺癌细胞中的细胞毒性^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Hederagenin (25 mg/kg; 口服; 共 11 天) 单独处理 NCI-H1299 异种异植的小鼠，不影响肿瘤生长。但与 Cisplatin (1 mg/kg) 具有协同作用，共同抑制肿瘤生长^[4]。
Hederagenin (50 mg/kg; 口服; 每天 1 次，共 21 天) 发挥抗炎和抗凋亡活性，减轻小鼠受 25% 乙醇引起的肝损伤^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

472.70

Formula

C₃₀H₄₈O₄

CAS 号

465-99-6

性状

固体

颜色

White to off-white

中文名称

常春藤皂苷元

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 50 mg/mL (105.78 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1155 mL	10.5775 mL	21.1551 mL
5 mM	0.4231 mL	2.1155 mL	4.2310 mL
10 mM	0.2116 mL	1.0578 mL	2.1155 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.29 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.29 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.95%

选择批次：

Data Sheet (644 KB) SDS (392 KB)

COA (290 KB) HNMR (299 KB) RP-HPLC (212 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Su-Hong Lu et al. Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats. Evid Based Complement Alternat Med, 2015, Oct 19 [Content Brief]

[2]. Diego Rodríguez-Hernández et al. Hederagenin as a triterpene template for the development of new antitumor compounds. Eur J Med Chem, 2015 Nov 13, 105:57-62 [Content Brief]

[3]. Chul Won Lee et al. Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice. Int Immunopharmacol, 2015 Dec, 29(2):528-37. [Content Brief]

[4]. Liu BX, et al. Hederagenin from the leaves of ivy (Hedera helix L.) induces apoptosis in human LoVo colon cells through the mitochondrial pathway. BMC Complement Altern Med. 2014 Oct 24;14:412. [Content Brief]

[5]. Kim GJ, et al. Hederagenin Supplementation Alleviates the Pro-Inflammatory and Apoptotic Response to Alcohol in Rats. Nutrients. 2017 Jan 6;9(1):41. [Content Brief]

[6]. Wang K, et al. Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells. Cell Death Dis. 2020 Aug 13;11(8):611. [Content Brief]

Hederagenin 相关分类

Cancer

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1155 mL	10.5775 mL	21.1551 mL	52.8877 mL
	5 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	10 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	15 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	20 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	25 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	30 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	40 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	50 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL
	60 mM	0.0353 mL	0.1763 mL	0.3526 mL	0.8815 mL
	80 mM	0.0264 mL	0.1322 mL	0.2644 mL	0.6611 mL
	100 mM	0.0212 mL	0.1058 mL	0.2116 mL	0.5289 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Hederagenin465-99-6常春藤皂苷元COXNF-κBCyclooxygenaseNuclear factor-κBNuclear factor-kappaBALDH2alcoholapoptosishederagenininflammatoryliver diseaseInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Hederagenin (Synonyms: 常春藤皂苷元)

Customer Review

Other Forms of Hederagenin:

MCE 顾客使用本产品发表的 3 篇科研文献

Hederagenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Hederagenin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Hederagenin (Synonyms: 常春藤皂苷元)

Customer Review

Other Forms of Hederagenin:

Hederagenin 相关抗体

MCE 顾客使用本产品发表的 3 篇科研文献

Hederagenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Hederagenin 相关抗体:

摩尔计算器

稀释计算器

Hederagenin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z